CareDx Reports 30% Revenue Growth in Testing Services, Forecasts Strong 2024 Financials

CareDx Reports Strong Growth in Testing Services Amid Financial Forecasts for 2024

CareDx, Inc., recognized as a leader in transplant patient care, announces promising preliminary unaudited financial results for the fourth quarter and full year of 2024. The company expects revenues for Q4 2024 to fall between $85 million and $86 million, marking an impressive year-over-year increase of approximately 30%. A significant contributor to this growth is the testing services segment, which anticipates revenues ranging from $62.5 million to $63.5 million. This represents a 35% increase compared to the previous year, driven by a projected testing volume of around 45,500, reflecting a 14% year-over-year rise. CareDx's robust performance in this area underscores its essential role in the transplant space, where timely and accurate testing is critical for patient outcomes.

In addition to the strong performance in testing services, CareDx foresees a steady contribution from its Digital Solutions and Products sectors, with an expected revenue of $11.4 million each. While the company anticipates a GAAP loss between $32 million and $34 million for Q4, adjusted EBITDA is projected to be a positive gain of $8 million to $9 million. This mixed financial outlook highlights the ongoing investments CareDx makes to enhance its service offerings and innovate in the transplant diagnostics field, aiming to balance growth with sustainable financial health. The anticipated total revenue for the entire year of 2024 stands at approximately $332 million to $333 million, alongside a GAAP loss forecast of $58 million to $60 million.

Looking ahead, CareDx sets ambitious revenue targets for 2025, projecting $370 million and aiming for $500 million by 2027, alongside achieving 20% adjusted EBITDA. John W. Hanna, the company's President and CEO, emphasizes the commitment to serving transplant patients and acknowledges the significant growth in testing services volume over the past six quarters. These figures indicate that CareDx is not only maintaining its position as a key player in the transplant industry but is also positioning itself for future growth and innovation in patient care.

In other relevant developments, CareDx's financial position strengthens with an expected cash and marketable securities balance of approximately $261 million as of December 31, 2024, reflecting a year-over-year increase of about $26 million. This solid financial foundation supports ongoing investments in technology and service improvements essential for enhancing patient care in transplantation. Full financial results are set to be released during the February 2025 earnings call, where further insights into the company's future strategies and performance will be shared.